Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    NCT01012817
Previous Study | Return to List | Next Study

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

This study has suspended participant recruitment.
(Completion of dose escalation phase)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: November 11, 2009
Last updated: October 20, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)